vimarsana.com

Page 365 - ஒன்றுபட்டது மாநிலங்களில் பத்திரங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CD Projekt S A of Class Action Lawsuit and Upcoming Deadline - OTGLF

Share this article Share this article NEW YORK, March 3, 2021 /PRNewswire/  Pomerantz LLP announces that a class action lawsuit has been filed against CD Projekt S.A. ( CD Projekt or the Company ) (OTCMKTS: OTGLF; OTGLY) and certain of its officers.  The class action, filed in the United States District Court for the Central District of California, and docketed under 21-cv-00354, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise, acquired CD Projekt securities between January 16, 2020 and December 17, 2020, inclusive (the Class Period ).  Plaintiff seeks to recover compensable damages caused by Defendants violations of the federal securities laws under the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder by the United States Securities and Exchange Commission, against the Company and certain of its top officials.

IAMGOLD Reports Assay Results from the Astoria Area Drilling Program on the Rouyn Gold Project, Quebec; Drilling Resumes on Lac Gamble Area

IAMGOLD Reports Assay Results from the Astoria Area Drilling Program on the Rouyn Gold Project, Quebec; Drilling Resumes on Lac Gamble Area
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Eli Lilly and Company logo. (PRNewsfoto/Eli Lilly and Company) INDIANAPOLIS, March 3, 2021 /PRNewswire/  Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress. Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may dem

FedNat Holding Company Reports Fourth Quarter and Full Year 2020 Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation. FedNat Holding Company Reports Fourth Quarter and Full Year 2020 Results FedNat Holding CompanyMarch 2, 2021 GMT SUNRISE, Fla., March 02, 2021 (GLOBE NEWSWIRE) FedNat Holding Company (the “Company”) (Nasdaq: FNHC) today reported results for the three and twelve months ended December 31, 2020. Q4 2020 highlights (as measured against the same three-month period last year, except where noted): Net loss of $32.9 million or $2.40 per diluted share Adjusted operating loss of $26.9 million or $1.96 per diluted share. $31.1 million, pre-tax, net of recoveries, of claims related to Hurricanes Delta, Zeta and Eta, which together impacted portions of Texas, Florida, Louisiana and Alabama, as previously communicated.

MaxLinear Announces Industry s First Quad-Port PHY Optimized for 2 5GBASE-T Enabling Cost-Effective 2 5G Ethernet Multiport Applications

The new GPY241 expands MaxLinear’s portfolio of Ethernet physical layer (PHY) transceivers and switches CARLSBAD, Calif.–(BUSINESS WIRE)–MaxLinear, Inc. (NYSE: MXL), a leading provider of radio frequency (RF), analog, digital and mixed-signal integrated circuits, announced today the extension of its Ethernet portfolio with the GPY241, a quad-port 2.5GBASE-T Ethernet PHY. The new device adds to the Company’s existing portfolio of 1 Gigabit PHYs, 2.5 Gigabit PHYs and 1 Gigabit switches. The GPY241 is the industry’s first quad-port PHY optimized for 2.5GBASE-T Ethernet and adds USXGMII interface capability. It enables switch and gateway manufacturers to provide multiple cost-effective 2.5G ports in High-Speed Switches, Gateways, and Routers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.